share
  • facebook
  • twitter
  • linked in
  • google+
back top

Pavesio Alessandra - Chief Scientific Officer

Pavesio Alessandra

Bioventus LLC
R&D
Durham, United States of America

Alessandra Pavesio is the Chief Science Officer at Bioventus, where she is responsible for leading R&D, Clinical and Regulatory Affairs, and providing strategic and operational leadership for the further growth of Bioventus products from early-stage development to commercial launch.

During Pavesio’s >20-year career, she has developed – from concept to bedside – more than 30 Class-III innovative medical devices, drugs and biologics, designed for treatment of osteoarthritis, and for regeneration of soft and hard tissues. A recognized opinion leader in cell based therapies, Pavesio revolutionized cartilage regeneration by conceiving and developing the first matrix assisted autologous chondrocyte implantation technology to reach the market. She has also served as chairperson of international regenerative medicine technology platforms and government advisory councils on innovation.

Prior to joining Bioventus, Pavesio held executive positions in Boston University, Anika Therapeutics and Fidia.

An accomplished innovator with 15 granted patented inventions on hyaluronon based technologies, Pavesio is the co-author of numerous peer reviewed publications.

5 February (Wednesday)

  • 16:30 - 18:00
    Session 3
    • 17:00 - 17:30
      Bioventus: Preclinical Characterization and Clinical Development Plans for PTP-001, a Novel Human Tissue Biologic in Development For The Treatment of Osteoarthritis.
      To date, all attempts to develop disease-modifying therapies for OA have failed, principally due to lack of clinical efficacy or safety issues. Such treatments have generally focused on modulation of a single target (e.g. a specific cytokine or enzyme/protease) whereas OA is a complex, mutifactorial disease process. PTP-001 is an effective tissue-derived treatment, with an inherent multi-modal MOA that can impact a number of pathologic pathways (including pain and tissue damage) which contribute to OA. This presentation will focus on the evidence and the development plans for PTP-001 as a regulated biologic product, in concordance with FDA guidance, as a novel approach for the treatment of OA and other musculoskeletal conditions.